Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Summary: Tanespimycin, a heat shock protein 90 (HSP90) inhibitor, induces apoptosis in drug‐sensitive and ‐resistant MM cell lines and in tumour cells from patients with relapsed MM. In this phase 1 dose‐escalation study, the safety, plasma pharmacokinetics, and biological/antitumour activity of tanespimycin were evaluated in heavily pretreated patients with relapsed/refractory MM. Tanespimycin (150–525 mg/m 2 ) was given on days 1, 4, 8, and 11 of each 3‐week cycle for up to 8 cycles. Non‐haematological AEs included diarrhoea (59%), back pain (35%), fatigue (38%), and nausea (35%); haematological AEs included anaemia (24%) and thrombocytopenia (21%). One patient (3%) achieved minimal response (MR), with a progression‐free survival (PFS) of 3 months, a 41% decrease from baseline in urine M protein, and a 33% decrease from baseline in serum M protein. Fifteen patients (52%) achieved SD with a median PFS of 2·1 months; 5/15 had reductions in serum M protein ranging from 7% to 38% and in urine M protein ranging from 6% to 91%. Mean HSP70 levels increased from day 1 h 0 to day 1 h 4 with further increases on day 11 h 0 and day 11 h 4, consistent with a therapeutic treatment effect. Tanespimycin monotherapy was well tolerated and demonstrated activity across all doses tested.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 5×
“(Bladé et al, 1998; Richardson et al, 2003) Investigators monitored antitumour responses for complete response (CR), near complete response (nCR), partial response (PR), minimal response (MR), stable disease (SD), and progressive disease (PD).”
BackgroundMethodSelf-citationHSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502 · cited 1×
“(Whitesell & Lindquist, 2005; Powers & Workman, 2006).”
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Cited by
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 891
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
Jhaveri, K., Taldone, T., Modi, S., & Chiosis, G. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.10.008 · Cited by 456
Inhibition of HSP90 molecular chaperones: moving into the clinic
Garcia-Carbonero, R., Carnero, A., & Paz-Ares, L. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70169-4 · Cited by 351
Hypoxia Inducible Factor Pathway Inhibitors as Anticancer Therapeutics
Burroughs, S. K., Kaluz, S., Wang, D., Wang, K., Van Meir, E. G., & Wang, B. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.17 · Cited by 140
Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010)
Ban, H. S., Uto, Y., & Nakamura, H. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.547477 · Cited by 42
Metadata
- Authors
- Richardson, P. G., Chanan‐Khan, A. A., Alsina, M., Albitar, M., Berman, D., Messina, M., Mitsiades, C. S., & Anderson, K. C.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2010-08
- Volume
- 150
- Issue
- 4
- Pages
- 438-445
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1562135226
- Cited by
- 80
- References
- 3
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study. https://app.cochat.ai/papers/10.1111/j.1365-2141.2010.08265.x
- The paper
- Richardson, P. G., Chanan‐Khan, A. A., Alsina, M., Albitar, M., Berman, D., Messina, M., Mitsiades, C. S., & Anderson, K. C. (2010). Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2010.08265.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.